Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | PRKDC | P78527 | 1/20 | 0.57 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25682965 | 0.95 | PIK3CA (0.58) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL25682966 | 0.93 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL25685461 | 0.93 | PIK3CA (0.69) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL24912829 | 0.91 | PIK3CA (0.72) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL24912818 | 0.91 | PIK3CA (0.72) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL30062187 | 0.91 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL24912832 | 0.91 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL30584316 | 0.91 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL26662434 | 0.91 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR | |
| SCHEMBL25683183 | 0.90 | PIK3CA (0.56) | PIK3CAPIK3CBPIK3CDPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136568-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136568-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CB 3/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.